Johnson & Johnson | 1Q 2025: Strong start to the year, but regional differences remain a challenge

The first quarter of 2025 delivered strong results for Johnson & Johnson across key areas. Profit growth, steady operational growth and advances in drug development signal that the company is well positioned for the rest of the year. While some segments face challenges, others show promising potential. What specifically is driving the current performance, where are new investments going, and how are investors responding?

What's happening?

Behind the scenes of the first quarter numbers, there is a clear shift in the company's strategy. Johnson & Johnson $JNJ is not only consolidating its strengths in pharmaceuticals and medical technology, but is also re-prioritizing toward innovation and new segments. Acquisitions in neurosciences and cardiology suggest that the company is purposefully expanding its reach beyond its traditional domains. The development of robotic solutions such as VELYS™ and OTTAVA indicates a drive to strengthen the technology side of care, while the consumer division…